{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:33:08Z","timestamp":1787009588008,"version":"build-2736575974"},"reference-count":66,"publisher":"Oxford University Press (OUP)","issue":"1175","license":[{"start":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T00:00:00Z","timestamp":1677283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by systemic inflammation and synovitis which evolve into joint destruction and deformity. Bone abnormalities are represented by marginal bone erosions and iuxta-articular and generalized osteoporosis. Overactivation of osteoclasts along with dysregulation of osteoblasts are the key events. Bone resorption is mediated by the receptor activator of nuclear factor (NF)-\u03baB (RANK) ligand (RANK-L), responsible for the differentiation, proliferation, and activation of osteoclasts. RANK-L binds its receptor RANK, localized on the surface of preosteoclasts and mature osteoclasts promoting osteoclastogenesis. High levels of RANK-L were demonstrated in active RA patients. Denosumab, a fully human monoclonal antibody, binds RANK-L and suppresses the RANK\u2013RANK-L signaling pathway leading to the inhibition of osteoclastogenesis. A retrospective analysis of published studies such as clinical trials evidenced the efficacy of denosumab in preventing bone erosion progression in RA patients.<\/jats:p>\n                  <jats:p>Key messages Key questions to answer in future include the following: Could denosumab be associated with other biologic therapies in RA patients? Could denosumab block the progression of bone damage in RA? Could denosumab be used for the prevention of bone erosion in RA?<\/jats:p>","DOI":"10.1093\/postmj\/qgad013","type":"journal-article","created":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T18:09:43Z","timestamp":1677348583000},"page":"976-984","source":"Crossref","is-referenced-by-count":8,"title":["Role of denosumab in bone erosions in rheumatoid arthritis"],"prefix":"10.1093","volume":"99","author":[{"given":"Silvia","family":"Stefania","sequence":"first","affiliation":[{"name":"University of Foggia Rheumatology Clinic, Department of Medical and Surgical Sciences, , Foggia, 71122 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Rotondo","sequence":"additional","affiliation":[{"name":"University of Foggia Rheumatology Clinic, Department of Medical and Surgical Sciences, , Foggia, 71122 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angiola","family":"Mele","sequence":"additional","affiliation":[{"name":"University of Foggia Rheumatology Clinic, Department of Medical and Surgical Sciences, , Foggia, 71122 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"Trotta","sequence":"additional","affiliation":[{"name":"University of Foggia Rheumatology Clinic, Department of Medical and Surgical Sciences, , Foggia, 71122 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Paolo","family":"Cantatore","sequence":"additional","affiliation":[{"name":"University of Foggia Rheumatology Clinic, Department of Medical and Surgical Sciences, , Foggia, 71122 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Addolorata","family":"Corrado","sequence":"additional","affiliation":[{"name":"University of Foggia Rheumatology Clinic, Department of Medical and Surgical Sciences, , Foggia, 71122 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,2,25]]},"reference":[{"key":"2023082210051188900_ref1","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med"},{"key":"2023082210051188900_ref2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ncprheum0036","article-title":"Mechanisms of disease: the link between RANKL and arthritic bone disease","volume":"1","author":"Schett","year":"2005","journal-title":"Nat Clin Pract Rheumatol"},{"key":"2023082210051188900_ref3","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1007\/s11033-021-06288-y","article-title":"Osteoblast role in the pathogenesis of rheumatoid arthritis","volume":"48","author":"Berardi","year":"2021","journal-title":"Mol Biol Rep"},{"key":"2023082210051188900_ref4","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1002\/jcp.29149","article-title":"Janus kinase inhibitors role in bone remodeling","volume":"235","author":"Maruotti","year":"2020","journal-title":"J Cell Physiol"},{"key":"2023082210051188900_ref5","doi-asserted-by":"crossref","first-page":"9087","DOI":"10.1007\/s11033-020-05910-9","article-title":"JAK\/STAT pathway and molecular mechanism in bone remodeling","volume":"47","author":"Sanpaolo","year":"2020","journal-title":"Mol Biol Rep"},{"key":"2023082210051188900_ref6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.coph.2018.03.006","article-title":"Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system","volume":"40","author":"Tanaka","year":"2018","journal-title":"Curr Opin Pharmacol"},{"key":"2023082210051188900_ref7","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3390\/ijms18061272","article-title":"Osteoblast role in rheumatic diseases","volume":"18","author":"Corrado","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2023082210051188900_ref8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/1759720X12438080","article-title":"The role of RANK ligand\/osteoprotegerin in rheumatoid arthritis","volume":"4","author":"Geusens","year":"2012","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2023082210051188900_ref9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/1529-0131(200002)43:2<259::AID-ANR4>3.0.CO;2-W","article-title":"Involvement of receptor activator of nuclear factor \u03baB ligand\/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis","volume":"43","author":"Takayanagi","year":"2000","journal-title":"Arthritis Rheum"},{"key":"2023082210051188900_ref10","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1002\/1529-0131(200011)43:11<2523::AID-ANR20>3.0.CO;2-Z","article-title":"Expression of osteoclast differentiation factor in rheumatoid arthritis","volume":"43","author":"Shigeyama","year":"2000","journal-title":"Arthritis Rheum"},{"key":"2023082210051188900_ref11","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/46303","article-title":"Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand","volume":"402","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"2023082210051188900_ref12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10238-010-0117-2","article-title":"Osteoclastogenesis and arthritis","volume":"11","author":"Maruotti","year":"2011","journal-title":"Clin Exp Med"},{"key":"2023082210051188900_ref13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00441-010-1086-1","article-title":"Osteoblast physiology in normal and pathological conditions","volume":"343","author":"Neve","year":"2011","journal-title":"Cell Tissue Res"},{"key":"2023082210051188900_ref14","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ebiom.2019.02.009","article-title":"Osteoblastic PLEKHO1 contributes to joint inflammation in rheumatoid arthritis","volume":"41","author":"He","year":"2019","journal-title":"EBioMedicine"},{"key":"2023082210051188900_ref15","first-page":"728610","article-title":"The role of citrullinated protein antibodies in predicting erosive disease in rheumatoid arthritis: a systematic literature review and meta-analysis","volume":"2015","author":"Jilani","journal-title":"Int J Rheumatol"},{"key":"2023082210051188900_ref16","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1002\/art.23943","article-title":"Induction of osteoclast-associated receptor, a key osteoclast costimulation molecule, in rheumatoid arthritis","volume":"58","author":"Herman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2023082210051188900_ref17","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1136\/ard.61.12.1047","article-title":"Receptor activator NF-\u03baB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis","volume":"61","author":"Crotti","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"2023082210051188900_ref18","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/rheumatology\/40.6.623","article-title":"Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint","volume":"40","author":"Haynes","year":"2001","journal-title":"Rheumatology"},{"key":"2023082210051188900_ref19","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/S0002-9440(10)63016-7","article-title":"TRANCE\/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis","volume":"159","author":"Pettit","year":"2001","journal-title":"Am J Pathol"},{"key":"2023082210051188900_ref20","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/annrheumdis-2018-214827","article-title":"Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2023082210051188900_ref21","first-page":"261","article-title":"How to read radiographs according to the Sharp\/van der Heijde method","volume":"27","author":"van der Heijde","year":"2000","journal-title":"J Rheumatol"},{"key":"2023082210051188900_ref22","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/ard.2006.068247","article-title":"High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study","volume":"67","author":"Syversen","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2023082210051188900_ref23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/14397595.2019.1703484","article-title":"Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: analysis of data from the DRIVE and DESIRABLE studies","volume":"31","author":"Takeuchi","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2023082210051188900_ref24","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3899\/jrheum.100829","article-title":"Relationship of focal erosions, bone mineral density, and parathyroid hormone in rheumatoid arthritis","volume":"38","author":"Rossini","year":"2011","journal-title":"J Rheumatol"},{"key":"2023082210051188900_ref25","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/jbmr.1793","article-title":"Structure and strength of the distal radius in female patients with rheumatoid arthritis: a case-control study","volume":"28","author":"Zhu","year":"2013","journal-title":"J Bone Miner Res"},{"key":"2023082210051188900_ref26","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/jbmr.2221","article-title":"Alterations of bone density, microstructure, and strength of the distal radius in male patients with rheumatoid arthritis: a case-control study with HR-pQCT","volume":"29","author":"Zhu","year":"2014","journal-title":"J Bone Miner Res"},{"key":"2023082210051188900_ref27","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrd3669","article-title":"Inflammatory bone loss: pathogenesis and therapeutic intervention","volume":"11","author":"Redlich","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"2023082210051188900_ref28","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/ncprheum0843","article-title":"Focal and generalized bone loss in rheumatoid arthritis: separate or similar concepts?","volume":"4","author":"Haugeberg","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"key":"2023082210051188900_ref29","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/annrheumdis-2012-202958","article-title":"Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies","volume":"73","author":"Kleyer","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2023082210051188900_ref30","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/01.bor.0000127824.42507.68","article-title":"Bone loss in inflammatory arthritis: mechanisms and treatment strategies","volume":"16","author":"Walsh","year":"2004","journal-title":"Curr Opin Rheumatol"},{"key":"2023082210051188900_ref31","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s00198-020-05360-w","article-title":"Effects of glucocorticoids on osteoporosis in rheumatoid arthritis: a systematic review and meta-analysis","volume":"31","author":"Wang","year":"2020","journal-title":"Osteoporos Int"},{"key":"2023082210051188900_ref32","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/art.11481","article-title":"Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission","volume":"50","author":"Molenaar","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2023082210051188900_ref33","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: different mechanisms of action and effects","volume":"48","author":"Baron","year":"2011","journal-title":"Bone"},{"key":"2023082210051188900_ref34","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos Int"},{"key":"2023082210051188900_ref35","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/jbmr.149","article-title":"Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies","volume":"25","author":"Reid","year":"2010","journal-title":"J Bone Miner Res"},{"key":"2023082210051188900_ref36","doi-asserted-by":"crossref","first-page":"154264","DOI":"10.1016\/j.metabol.2020.154264","article-title":"Extra-skeletal effects of bisphosphonates","volume":"110","author":"Panagiotakou","year":"2020","journal-title":"Metabolism"},{"key":"2023082210051188900_ref37","doi-asserted-by":"crossref","DOI":"10.1186\/ar2877","article-title":"A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis","volume":"11","author":"Le Goff","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"2023082210051188900_ref38","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1002\/art.21824","article-title":"Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis","volume":"54","author":"Jarrett","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2023082210051188900_ref39","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/acr.23133","article-title":"Repair of bone erosion in rheumatoid arthritis by denosumab: a high-resolution peripheral quantitative computed tomography study","volume":"69","author":"Yue","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2023082210051188900_ref40","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1210\/er.2004-0006","article-title":"Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use","volume":"26","author":"Hodsman","year":"2005","journal-title":"Endocr Rev"},{"key":"2023082210051188900_ref41","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/art.40156","article-title":"Effects of teriparatide on joint erosions in rheumatoid arthritis: a randomized controlled trial","volume":"69","author":"Solomon","year":"2017","journal-title":"Arthritis Rheum"},{"key":"2023082210051188900_ref42","doi-asserted-by":"crossref","first-page":"210","DOI":"10.4161\/mabs.1.3.8592","article-title":"Denosumab","volume":"1","author":"Pageau","year":"2009","journal-title":"MAbs"},{"key":"2023082210051188900_ref43","first-page":"S293","article-title":"The pharmacokinetics of denosumab (AMG 162) following various multiple subcutaneous dosing regimens in postmenopausal women with low bone mass","volume":"20","author":"Peterson","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2023082210051188900_ref44","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/BOR.0b013e32832ca41c","article-title":"Denosumab update","volume":"21","author":"Lewiecki","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"2023082210051188900_ref45","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s11926-009-0027-z","article-title":"Denosumab for joints and bones","volume":"11","author":"Lewiecki","year":"2009","journal-title":"Curr Rheumatol Rep"},{"key":"2023082210051188900_ref46","first-page":"47","article-title":"The contribution of cortical and trabecular tissues to bone strength: insights from denosumab studies","volume":"10","author":"Iolascon","year":"2013","journal-title":"Clin Cases Miner Bone Metab"},{"key":"2023082210051188900_ref47","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023082210051188900_ref48","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40268-016-0146-8","article-title":"Assessment of distal radius bone mineral density in osteoporosis patients receiving denosumab, including those with rheumatoid arthritis and those receiving oral glucocorticoids","volume":"16","author":"Matsuno","year":"2016","journal-title":"Drugs R D"},{"key":"2023082210051188900_ref49","first-page":"253","article-title":"THU0164 comparison of the effect of denosumab and alendronate on bone density and microarchitecture at the distal radius in rheumatoid arthritis females with low bone mass: a randomized controlled trial","volume":"74","author":"Wong","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2023082210051188900_ref50","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12020-012-9696-x","article-title":"Skeletal and extraskeletal actions of denosumab","volume":"42","author":"Sinningen","year":"2012","journal-title":"Endocrine"},{"key":"2023082210051188900_ref51","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1136\/ard.2009.112920","article-title":"Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates","volume":"69","author":"Dore","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2023082210051188900_ref52","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00774-017-0848-1","article-title":"Effects of denosumab treatment on bone mineral density and joint destruction in patients with rheumatoid arthritis","volume":"36","author":"Mochizuki","year":"2018","journal-title":"J Bone Miner Metab"},{"key":"2023082210051188900_ref53","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/art.23417","article-title":"Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial","volume":"58","author":"Cohen","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2023082210051188900_ref54","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/acr.20172","article-title":"Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis","volume":"62","author":"Sharp","year":"2010","journal-title":"Arthritis Care Res"},{"key":"2023082210051188900_ref55","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/acr.20004","article-title":"Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients","volume":"62","author":"Deodhar","year":"2010","journal-title":"Arthritis Care Res"},{"key":"2023082210051188900_ref56","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/annrheumdis-2015-208052","article-title":"Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)\u2014a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial","volume":"75","author":"Takeuchi","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2023082210051188900_ref57","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/rheumatology\/key416","article-title":"Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study","volume":"58","author":"Ishiguro","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2023082210051188900_ref58","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/art.39075","article-title":"Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab","volume":"67","author":"Curtis","year":"2015","journal-title":"Arthritis Rheum"},{"key":"2023082210051188900_ref59","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jbspin.2016.05.010","article-title":"Efficacy of denosumab combined with bDMARDs on radiographic progression in rheumatoid arthritis","volume":"84","author":"Hasegawa","year":"2017","journal-title":"Joint Bone Spine"},{"key":"2023082210051188900_ref60","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3899\/jrheum.161270","article-title":"Occurrence of serious infection in patients with rheumatoid arthritis treated with biologics and denosumab observed in a clinical setting","volume":"45","author":"Arthur","year":"2018","journal-title":"J Rheumatol"},{"key":"2023082210051188900_ref61","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s00198-018-4492-y","article-title":"Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-na\u00efve rheumatoid arthritis","volume":"29","author":"Ebina","year":"2018","journal-title":"Osteoporos Int"},{"key":"2023082210051188900_ref62","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-019-3589-8","article-title":"Comparative study of the inhibitory effect on bone erosion progression with denosumab treatment and conventional treatment in rheumatoid arthritis patients: study protocol for an open-label randomized controlled trial by HR-pQCT","volume":"20","author":"Iwamoto","year":"2019","journal-title":"Trials"},{"key":"2023082210051188900_ref63","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001249","article-title":"Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction","volume":"6","author":"Tanaka","year":"2020","journal-title":"RMD Open"},{"key":"2023082210051188900_ref64","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.3899\/jrheum.201376","article-title":"Effects of denosumab in Japanese patients with rheumatoid arthritis treated with conventional antirheumatic drugs: 36-month extension of a phase III study","volume":"48","author":"Tanaka","year":"2021","journal-title":"J Rheumatol"},{"key":"2023082210051188900_ref65","doi-asserted-by":"crossref","DOI":"10.1186\/s13018-021-02271-2","article-title":"Effect of denosumab switched from bisphosphonates in preventing joint destruction in postmenopausal rheumatoid arthritis patients with anti-cyclic citrullinated peptide antibodies","volume":"16","author":"Mori","year":"2021","journal-title":"J Orthop Surg Res"},{"key":"2023082210051188900_ref66","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/annrheumdis-2021-219846","article-title":"Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial","volume":"80","author":"So","year":"2021","journal-title":"Ann Rheum Dis"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/99\/1175\/976\/51208264\/qgad013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/99\/1175\/976\/51208264\/qgad013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T06:07:33Z","timestamp":1692684453000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/99\/1175\/976\/7058219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,25]]},"references-count":66,"journal-issue":{"issue":"1175","published-online":{"date-parts":[[2023,2,25]]},"published-print":{"date-parts":[[2023,8,22]]}},"URL":"https:\/\/doi.org\/10.1093\/postmj\/qgad013","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2023,2,25]]}}}